

REFERENCES

- Abdullahi, S., Jäkel, M., Behrend, S. J., Steiger, K., Topping, G., Krabbe, T., Colombo, A., Sandig, V., Schiergens, T. S., Thasler, W. E., Werner, J., Lichtenthaler, S. F., Schmid, R. M., Ebert, O., & Altomonte, J. (2018). A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma. *Journal of virology*, *92*(23), e01386-18. <https://doi.org/10.1128/JVI.01386-18>
- Aref, S., Bailey, K., & Fielding, A. (2016). Measles to the rescue: a review of oncolytic measles virus. *Viruses*, *8*(10), 294.
- Asafo-Agyei, K. O., & Samant, H. Hepatocellular Carcinoma. StatPearls. Retrieved from <https://www.ncbi.nlm.nih.gov/books/NBK559177/>
- Blechacz, B., & Russell, S. J. (2008). Measles virus as an oncolytic vector platform. *Current gene therapy*, *8*(3), 162–175. <https://doi.org/10.2174/156652308784746459>
- Blechacz, B., Splinter, P. L., Greiner, S., Myers, R., Peng, K. W., Federspiel, M. J., ... & LaRusso, N. F. (2006). Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. *Hepatology*, *44*(6), 1465-1477.
- Boulares, A. H., Yakovlev, A. G., Ivanova, V., Stoica, B. A., Wang, G., Iyer, S., & Smulson, M. (1999). Role of poly (ADP-ribose) polymerase (PARP) cleavage in apoptosis: caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. *Journal of Biological Chemistry*, *274*(33), 22932-22940.
- Branković, M., Jovanović, I., Dukić, M., Radonjić, T., Oprić, S., Klašnja, S., & Zdravković, M. (2022). Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis. *International journal of molecular sciences*, *23*(9), 5146. <https://doi.org/10.3390/ijms23095146>
- Brehm-Stecher, B. F. (2014). Flow cytometry. *Encyclopedia of Food Microbiology*, 943–953. <https://doi.org/10.1016/b978-0-12-384730-0.00127-0>
- Burton, C., & Barteel, E. (2019). Syncytia Formation in Oncolytic Virotherapy. *Molecular therapy oncolytics*, *15*, 131–139. <https://doi.org/10.1016/j.omto.2019.09.006>
- Burton, C., Barteel, M. Y., & Barteel, E. (2019). Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus. *Oncolytic virotherapy*, *8*, 57–69. <https://doi.org/10.2147/OV.S220420>
- Chang, J. F., Chen, P. J., Sze, D. Y., Reid, T., Bartlett, D., Kirn, D. H., & Liu, T. C. (2009). Oncolytic virotherapy for advanced liver tumours. *Journal of cellular and molecular medicine*, *13*(7), 1238–1247. <https://doi.org/10.1111/j.1582-4934.2008.00563.x>
- Chaurasiya, S., Fong, Y., & Warner, S. G. (2021). Oncolytic Virotherapy for Cancer: Clinical Experience. *Biomedicines*, *9*(4), 419. <https://doi.org/10.3390/biomedicines9040419>
- Chen, W., & Xu, W. H. (2015). β -Actin as a loading control: Less than 2 μ g of total protein should be loaded. *Electrophoresis*, *36*(17), 2046–2049. <https://doi.org/10.1002/elps.201500138>

- Chen, A., Zhang, Y., Meng, G., Jiang, D., Zhang, H., Zheng, M., ... & Wei, J. (2017). Oncolytic measles virus enhances antitumour responses of adoptive CD8+ NKG2D+ cells in hepatocellular carcinoma treatment. *Scientific reports*, 7(1), 5170.
- Chidambaranathan-Reghupaty, S., Fisher, P. B., & Sarkar, D. (2021). Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. *Advances in cancer research*, 149, 1–61. <https://doi.org/10.1016/bs.acr.2020.10.001>
- Chu, Y. J., Yang, H. I., Wu, H. C., Lee, M. H., Liu, J., Wang, L. Y., Lu, S. N., Jen, C. L., You, S. L., Santella, R. M., & Chen, C. J. (2018). Aflatoxin B1 exposure increases the risk of hepatocellular carcinoma associated with hepatitis C virus infection or alcohol consumption. *European journal of cancer (Oxford, England : 1990)*, 94, 37–46. <https://doi.org/10.1016/j.ejca.2018.02.010>
- Colagrande, S., Inghilesi, A. L., Aburas, S., Taliani, G. G., Nardi, C., & Marra, F. (2016). Challenges of advanced hepatocellular carcinoma. *World journal of gastroenterology*, 22(34), 7645–7659. <https://doi.org/10.3748/wjg.v22.i34.7645>
- Cook, M., & Chauhan, A. (2020). Clinical Application of Oncolytic Viruses: A Systematic Review. *International journal of molecular sciences*, 21(20), 7505. <https://doi.org/10.3390/ijms21207505>
- Davola, M. E., & Mossman, K. L. (2019). Oncolytic viruses: how "lytic" must they be for therapeutic efficacy?. *Oncoimmunology*, 8(6), e1581528. <https://doi.org/10.1080/2162402X.2019.1596006>
- Dhiman, N., Jacobson, R. M., & Poland, G. A. (2004). Measles virus receptors: SLAM and CD46. *Reviews in medical virology*, 14(4), 217–229. <https://doi.org/10.1002/rmv.430>
- Do, M. H., To, P. K., Cho, Y. S., Kwon, S. Y., Hwang, E. C., Choi, C., ... & Jung, C. (2018). Targeting CD46 enhances anti-tumoral activity of adenovirus type 5 for bladder cancer. *International journal of molecular sciences*, 19(9), 2694.
- Engeland, C. E., & Ungerechts, G. (2021). Measles Virus as an Oncolytic Immunotherapy. *Cancers*, 13(3), 544. <https://doi.org/10.3390/cancers13030544>
- Faghihkorhassani, A., Dalvand, A., Derafsh, E., Tavakoli, F., Younis, N. K., Yasamineh, S., ... & Shokri, P. (2023). The role of oncolytic virotherapy and viral oncogenes in the cancer stem cells: a review of virus in cancer stem cells. *Cancer Cell International*, 23(1), 250.
- Farhangnia, P., Ghomi, S. M., Mollazadehghomi, S., Nickho, H., Akbarpour, M., & Delbandi, A. A. (2023). SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy. *Frontiers in Immunology*, 14, 1174138.
- Ferguson, L. R., Chen, H., Collins, A. R., Connell, M., Damia, G., Dasgupta, S., Malhotra, M., Meeker, A. K., Amedei, A., Amin, A., Ashraf, S. S., Aquilano, K., Azmi, A. S., Bhakta, D., Bilsland, A., Boosani, C. S., Chen, S., Ciriolo, M. R., Fujii, H., Guha, G., ... Maxwell, C. A. (2015). Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. *Seminars in cancer biology*, 35 Suppl(Suppl), S5–S24. <https://doi.org/10.1016/j.semcancer.2015.03.005>
- Gain, C., Song, S., Angtuaco, T., Satta, S., & Kelesidis, T. (2023). The role of oxidative stress in the pathogenesis of infections with coronaviruses. *Frontiers in microbiology*, 13, 1111930. <https://doi.org/10.3389/fmicb.2022.1111930>

- Geng, Y., Faber, K. N., de Meijer, V. E., Blokzijl, H., & Moshage, H. (2021). How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?. *Hepatology international*, 15(1), 21–35. <https://doi.org/10.1007/s12072-020-10121-2>
- Geschwind J. F. (2015). Locoregional Therapy for Patients With Hepatocellular Carcinoma. *Gastroenterology & hepatology*, 11(10), 698–700.
- Gilda, J. E., Ghosh, R., Cheah, J. X., West, T. M., Bodine, S. C., & Gomes, A. V. (2015). Western Blotting Inaccuracies with Unverified Antibodies: Need for a Western Blotting Minimal Reporting Standard (WBMRS). *PloS one*, 10(8), e0135392. <https://doi.org/10.1371/journal.pone.0135392>
- Gutiérrez, S., Pirolles, E., Yvon, M., Baecker, V., Michalakakis, Y., & Blanc, S. (2015). The Multiplicity of Cellular Infection Changes Depending on the Route of Cell Infection in a Plant Virus. *Journal of virology*, 89(18), 9665–9675. <https://doi.org/10.1128/JVI.00537-15>
- Guseva, S., Milles, S., Blackledge, M., & Ruigrok, R. W. H. (2019). The Nucleoprotein and Phosphoprotein of Measles Virus. *Frontiers in microbiology*, 10, 1832. <https://doi.org/10.3389/fmicb.2019.01832>
- Huang, A., Yang, X. R., Chung, W. Y., Dennison, A. R., & Zhou, J. (2020). Targeted therapy for hepatocellular carcinoma. *Signal transduction and targeted therapy*, 5(1), 146. <https://doi.org/10.1038/s41392-020-00264-x>
- Inchingolo, R., Posa, A., Mariappan, M., & Spiliopoulos, S. (2019). Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. *World journal of gastroenterology*, 25(32), 4614–4628. <https://doi.org/10.3748/wjg.v25.i32.4614>
- Jhawar, S. R., Thandoni, A., Bommareddy, P. K., Hassan, S., Kohlhapp, F. J., Goyal, S., Schenkel, J. M., Silk, A. W., & Zloza, A. (2017). Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies. *Frontiers in oncology*, 7, 202. <https://doi.org/10.3389/fonc.2017.00202>
- Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015). Oncolytic viruses: a new class of immunotherapy drugs. *Nature reviews. Drug discovery*, 14(9), 642–662. <https://doi.org/10.1038/nrd4663>
- Keller, B. A., & Bell, J. C. (2016). Oncolytic viruses—immunotherapeutics on the rise. *Journal of Molecular Medicine*, 94, 979–991.
- Kern, L., Mittenbühler, M. J., Vesting, A. J., Ostermann, A. L., Wunderlich, C. M., & Wunderlich, F. T. (2018). Obesity-Induced TNF α and IL-6 Signaling: The Missing Link between Obesity and Inflammation-Driven Liver and Colorectal Cancers. *Cancers*, 11(1), 24. <https://doi.org/10.3390/cancers11010024>
- Kielkopf, C. L., Bauer, W., & Urbatsch, I. L. (2020). Bradford Assay for Determining Protein Concentration. *Cold Spring Harbor protocols*, 2020(4), 102269. <https://doi.org/10.1101/pdb.prot102269>
- Koulouris, A., Tsagkaris, C., Spyrou, V., Pappa, E., Troullinou, A., & Nikolaou, M. (2021). Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. *Journal of hepatocellular carcinoma*, 8, 387–401. <https://doi.org/10.2147/JHC.S300182>

- Kudo M. (2022). New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma. *International journal of clinical oncology*, 27(7), 1110–1119. <https://doi.org/10.1007/s10147-022-02166-0>
- Langie, S. A., Koppen, G., Desaulniers, D., Al-Mulla, F., Al-Temaimi, R., Amedei, A., Azqueta, A., Bisson, W. H., Brown, D. G., Brunborg, G., Charles, A. K., Chen, T., Colacci, A., Darroudi, F., Forte, S., Gonzalez, L., Hamid, R. A., Knudsen, L. E., Leyns, L., Lopez de Cerain Salsamendi, A., ... Collins, A. R. (2015). Causes of genome instability: the effect of low dose chemical exposures in modern society. *Carcinogenesis*, 36 Suppl 1(Suppl 1), S61–S88. <https://doi.org/10.1093/carcin/bgv031>
- Lampe, J., Bossow, S., Weiland, T., Smirnow, I., Lehmann, R., Neubert, W., ... & Lauer, U. M. (2013). An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis. *Gene therapy*, 20(11), 1033-1041.
- Lee, U. E., & Friedman, S. L. (2011). Mechanisms of hepatic fibrogenesis. *Best practice & research. Clinical gastroenterology*, 25(2), 195–206. <https://doi.org/10.1016/j.bpg.2011.02.005>
- Liu, C. H., Tai, C. J., Kuo, Y. T., Chang, S. S., & Lin, L. T. (2023). Combination of Oncolytic Measles Virus and Ursolic Acid Synergistically Induces Oncolysis of Hepatocellular Carcinoma Cells. *Viruses*, 15(6), 1294. <https://doi.org/10.3390/v15061294>
- Liu, C. Y., Chen, K. F., & Chen, P. J. (2015). Treatment of Liver Cancer. *Cold Spring Harbor perspectives in medicine*, 5(9), a021535. <https://doi.org/10.1101/cshperspect.a021535>
- Lohitesh, K., Chowdhury, R., & Mukherjee, S. (2018). Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. *Cancer cell international*, 18, 1-15.
- Lotfollahzadeh, S., Recio-Boiles, A., & Babiker, H. M. Liver Cancer. *StatPearls*. Retrieved from <https://www.ncbi.nlm.nih.gov/books/NBK448337/>
- Lurje, I., Czigany, Z., Bednarsch, J., Roderburg, C., Isfort, P., Neumann, U. P., & Lurje, G. (2019). Treatment Strategies for Hepatocellular Carcinoma – a Multidisciplinary Approach. *International journal of molecular sciences*, 20(6), 1465. <https://doi.org/10.3390/ijms20061465>
- Ma, Y., Lee, G., Heo, S. Y., & Roh, Y. S. (2021). Oxidative stress is a key modulator in the development of nonalcoholic fatty liver disease. *Antioxidants*, 11(1), 91.
- Mahmood, T., & Yang, P. C. (2012). Western blot: technique, theory, and trouble shooting. *North American journal of medical sciences*, 4(9), 429–434. <https://doi.org/10.4103/1947-2714.100998>
- Matsushita, H., & Takaki, A. (2019). Alcohol and hepatocellular carcinoma. *BMJ open gastroenterology*, 6(1), e000260. <https://doi.org/10.1136/bmjgast-2018-000260>
- Michelotti, A., de Scordilli, M., Palmero, L., Guardascione, M., Masala, M., Roncato, R., Foltran, L., Ongaro, E., & Puglisi, F. (2021). NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. *Cells*, 10(8), 2034. <https://doi.org/10.3390/cells10082034>
- Msaouel, P., Iankov, I. D., Dispenzieri, A., & Galanis, E. (2012). Attenuated oncolytic measles virus strains as cancer therapeutics. *Current pharmaceutical biotechnology*, 13(9), 1732–1741. <https://doi.org/10.2174/138920112800958896>

- Ong, H. T., Federspiel, M. J., Guo, C. M., Ooi, L. L., Russell, S. J., Peng, K. W., & Hui, K. M. (2013). Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. *Journal of hepatology*, 59(5), 999-1006.
- Palumbo, M. O., Kavan, P., Miller, W. H., Jr, Panasci, L., Assouline, S., Johnson, N., Cohen, V., Patenaude, F., Pollak, M., Jagoe, R. T., & Batist, G. (2013). Systemic cancer therapy: achievements and challenges that lie ahead. *Frontiers in pharmacology*, 4, 57. <https://doi.org/10.3389/fphar.2013.00057>
- Pellegata, N. S., Berriel Diaz, M., Rohm, M., & Herzig, S. (2022). Obesity and cancer-extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases. *Cancer metastasis reviews*, 41(3), 517–547. <https://doi.org/10.1007/s10555-022-10058-y>
- Philips, C. A., Rajesh, S., Nair, D. C., Ahamed, R., Abduljaleel, J. K., & Augustine, P. (2021). Hepatocellular Carcinoma in 2021: An Exhaustive Update. *Cureus*, 13(11), e19274. <https://doi.org/10.7759/cureus.19274>
- Plattet, P., Alves, L., Herren, M., & Aguilar, H. C. (2016). Measles Virus Fusion Protein: Structure, Function and Inhibition. *Viruses*, 8(4), 112. <https://doi.org/10.3390/v8040112>
- Robinson, S., & Galanis, E. (2017). Potential and clinical translation of oncolytic measles viruses. *Expert opinion on biological therapy*, 17(3), 353–363. <https://doi.org/10.1080/14712598.2017.1288713>
- Russell, L., & Peng, K. W. (2018). The emerging role of oncolytic virus therapy against cancer. *Chinese clinical oncology*, 7(2), 16.
- Russo, F. P., Zanetto, A., Pinto, E., Battistella, S., Penzo, B., Burra, P., & Farinati, F. (2022). Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?. *International journal of molecular sciences*, 23(1), 500. <https://doi.org/10.3390/ijms23010500>
- Salete-Granado, D., Carbonell, C., Puertas-Miranda, D., Vega-Rodríguez, V. J., García-Macia, M., Herrero, A. B., & Marcos, M. (2023). Autophagy, Oxidative Stress, and Alcoholic Liver Disease: A Systematic Review and Potential Clinical Applications. *Antioxidants*, 12(7), 1425.
- Seymour, L. W., & Fisher, K. D. (2016). Oncolytic viruses: finally delivering. *British journal of cancer*, 114(4), 357-361.
- Shen, C., Jiang, X., Li, M., & Luo, Y. (2023). Hepatitis virus and hepatocellular carcinoma: Recent advances. *Cancers*, 15(2), 533.
- Shen, Z., Liu, X., Fan, G., Na, J., Liu, Q., Lin, F., Zhang, Z., & Zhong, L. (2023). Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages. *Journal of translational medicine*, 21(1), 842. <https://doi.org/10.1186/s12967-023-04709-z>
- Sigma-Aldrich. (n.d.). 96992 Cell Counting Kit - 8. Retrieved on December 20, 2023 from <https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/381/017/96992dat.pdf>
- Singal, A. G., Kanwal, F., & Llovet, J. M. (2023). Global trends in hepatocellular carcinoma epidemiology: Implications for screening, prevention and therapy. *Nature Reviews Clinical Oncology*, 1-21.

- Singh, P. K., Doley, J., Kumar, G. R., Sahoo, A. P., & Tiwari, A. K. (2012). Oncolytic viruses & their specific targeting to tumour cells. *The Indian journal of medical research*, *136*(4), 571–584.
- Smale, S. T. (2010). Luciferase assay. *Cold Spring Harbor Protocols*, *2010*(5), pdb-prot5421.
- Sugiyama, T., Yoneda, M., Kuraishi, T., Hattori, S., Inoue, Y., Sato, H., & Kai, C. (2013). Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment. *Gene Therapy*, *20*(3), 338-347.
- Sukumaran, A., Sweetey, V. K., Vikas, B., & Joseph, B. (2023). Cytotoxicity and Cell Viability Assessment of Biomaterials. In Cytotoxicity-Understanding Cellular Damage and Response. *Intechopen*.
- Sun, B., & Karin, M. (2013). Inflammation and liver tumorigenesis. *Frontiers of medicine*, *7*, 242-254.
- Suresh, D., Srinivas, A. N., & Kumar, D. P. (2020). Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. *Frontiers in oncology*, *10*, 601710. <https://doi.org/10.3389/fonc.2020.601710>
- Tai, C. J., Liu, C. H., Pan, Y. C., Wong, S. H., Tai, C. J., Richardson, C. D., & Lin, L. T. (2019). Chemovirotherapeutic Treatment Using Camptothecin Enhances Oncolytic Measles Virus-Mediated Killing of Breast Cancer Cells. *Scientific reports*, *9*(1), 6767. <https://doi.org/10.1038/s41598-019-43047-3>
- Tan, H. K., Yates, E., Lilly, K., & Dhanda, A. D. (2020). Oxidative stress in alcohol-related liver disease. *World journal of hepatology*, *12*(7), 332–349. <https://doi.org/10.4254/wjh.v12.i7.332>
- Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019). A global view of hepatocellular carcinoma: trends, risk, prevention and management. *Nature reviews. Gastroenterology & hepatology*, *16*(10), 589–604. <https://doi.org/10.1038/s41575-019-0186-y>
- Zhu, L., Lei, Y., Huang, J., An, Y., Ren, Y., Chen, L., Zhao, H., & Zheng, C. (2023). Recent advances in oncolytic virus therapy for hepatocellular carcinoma. *Frontiers in oncology*, *13*, 1172292. <https://doi.org/10.3389/fonc.2023.1172292>